Viridian Therapeutics (VRDN.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov6

Viridian Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 70.57 M (forecast USD 11.72 M), actual EPS USD -0.3444 (forecast USD -1.02)

04:00

Viridian Therapeutics released FY2025 9 Months earnings on November 5 (EST), actual revenue USD 70.72 M, actual EPS USD -2.2181

04:00

Nov5

Viridian Therapeutics Receives Buy Rating from Analyst, Drug Development Progresses Smoothly

18:56

Nov3

Viridian Therapeutics Set to Launch Veligrotug in Mid-2026

18:36

Oct21

Viridian Therapeutics Launches Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

20:01

Oct20

Viridian Therapeutics Enters into Financing Agreement with DRI Healthcare and Anticipates Submitting BLA for VELIGROTUG

11:40

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 70.57 M, Net Income -28.17 M, EPS -0.3444

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 75 K, Net Income -81.98 M, EPS -1.0047

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 72 K, Net Income -70.69 M, EPS -0.8689

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More